Abciximab is an oral cell cycle protein-dependent kinase CDK4/6 inhibitor and the only CDK4/6 inhibitor approved as a stand-alone therapy for the treatment of HR+/HER2- advanced or recurrent breast cancer.In HR+, HER2- breast cancer cells, CDK4 and CDK6 promote phosphorylation of retinoblastoma-forming proteins and drive cell cycle advancement and cell proliferation.Abciximab inhibits the phosphorylation of Rb and blocks cell progression from the G1 to the S phase of the cell cycle, leading to cellular senescence and apoptosis.

In December 2020, abciximil was approved in China for the treatment of locally advanced or metastatic breast cancer that is hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+HER2-).It is worth noting that it was approved for both first-line and second-line treatment, and both are dosing regimens in combination with endocrine therapy.